Preclinical Pharmacology and Opioid Combinations

Pain Medicine

Volumn 13, Issue SUPPL. 1, 2012, Pages

  Pasternak, Gavril W ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Analgesia; Combinations; MOR 1; Morphine; Mu Receptor; Opioid; Synergy

Indexed keywords

ALFENTANIL; CODEINE; DIAMORPHINE; FENTANYL; GROWTH HORMONE; LEVOMETHADONE; METHADONE; MORPHINE; MORPHINE 6 ACETATE; MU OPIATE RECEPTOR; OPIATE; OXYCODONE; OXYMORPHONE; PETHIDINE; PROLACTIN; TESTOSTERONE;

ANALGESIA; CONFOCAL MICROSCOPY; CROSS TOLERANCE; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG TOLERANCE; EXON; GASTROINTESTINAL TRANSIT; GENETIC ANALYSIS; HUMAN; MOUSE STRAIN; NONHUMAN; PROTEIN PROCESSING; RESPIRATION DEPRESSION; REVIEW; SPINAL CORD;

EID: 84858390157     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2012.01335.x     Document Type: Article

References (27)

1. American Society of Anesthesiologists Task Force on Acute Pain Management. Practice guidelines for acute pain management in the perioperative setting: An updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. Anesthesiology 2004;100:1573-81.
2. Lauretti GR, Oliveira GM, Pereira NL. Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients. Br J Cancer 2003;89:2027-30.
3. Mercadante S, Villari P, Ferrera P, Casuccio A. Addition of a second opioid may improve opioid response in cancer pain: Preliminary data. Support Care Cancer 2004;12:762-6.
4. Pasternak GW. The pharmacology of mu analgesics: From patients to genes. Neuroscientist 2001;7:220-31.
5. Davis MP, Pasternak GW. Chapter 1, opioid receptors and opioid pharmacodynamics. In: Davis MP, Glare PA, Hardy J, Quigley C, eds. Opioids in Cancer Pain, 2nd edition. Oxford: Oxford University Press; 2009:43-52.
6. Rossi GC, Brown GP, Leventhal L, Yang K, Pasternak GW. Novel receptor mechanisms for heroin and morphine-6 beta-glucuronide analgesia. Neurosci Lett 1996;216:1-4.
7. Brown GP, Yang K, King MA, etal. 3-Methoxynaltrexone, a selective heroin/morphine-6beta-glucuronide antagonist. FEBS Lett 1997;412:35-8.
8. Pasternak GW. Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacol Sci 2001;22:67-70.
9. Zelcer S, Kolesnikov Y, Kovalyshyn I, Pasternak DA, Pasternak GW. Selective potentiation of opioid analgesia by nonsteroidal anti-inflammatory drugs. Brain Res 2005;1040:151-6.
10. Gatti A, Sabato E, Di Paolo AR, Mammucari M, Sabato AF. Oxycodone/paracetamol: A low-dose synergic combination useful in different types of pain. Clin Drug Investig 2010;30(suppl 2):3-14.
11. Blumenthal S, Min K, Marquardt M, Borgeat A. Postoperative intravenous morphine consumption, pain scores, and side effects with perioperative oral controlled-release oxycodone after lumbar discectomy. Anesth Analg 2007;105:233-7.
12. Jamison RN, Raymond SA, Slawsby EA, Nedeljkovic SS, Katz NP. Opioid therapy for chronic noncancer back pain. A randomized prospective study. Spine 1998;23:2591-600.
13. Bolan EA, Tallarida RJ, Pasternak GW. Synergy between mu opioid ligands: Evidence for functional interactions among mu opioid receptor subtypes. J Pharmacol Exp Ther 2002;303:557-62.
14. Pasternak GW. Opioid pharmacotherapy: From receptor to bedside. In: Inturrisi CE, Nicholson B, Pasternak GW, eds. Dual-Opioid Therapy. International Congress and Symposium Series 271. London: Royal Society of Medicine Press; 2009:1-10.
15. Pasternak GW. Molecular insights into mu opioid pharmacology: From the clinic to the bench. Clin J Pain 2010;26(suppl 10):S3-9.
16. Pan YX, Xu J, Xu M, etal. Involvement of exon 11-associated variants of the mu opioid receptor MOR-1 in heroin, but not morphine, actions. Proc Natl Acad Sci U S A 2009;106:4917-22.
17. Pasternak DA, Pan L, Xu J, etal. Identification of three new alternatively spliced variants of the rat mu opioid receptor gene: Dissociation of affinity and efficacy. J Neurochem 2004;91:881-90.
18. Pan YX, Xu J, Bolan E, etal. Identification and characterization of three new alternatively spliced mu-opioid receptor isoforms. Mol Pharmacol 1999;56:396-403.
19. Pan YX, Xu J, Bolan E, etal. Isolation and expression of a novel alternatively spliced mu opioid receptor isoform, MOR-1F. FEBS Lett 2000;466:337-40.
20. Pan YX, Xu J, Mahurter L, etal. Generation of the mu opioid receptor (MOR-1) protein by three new splice variants of the Oprm gene. Proc Natl Acad Sci U S A 2001;98:14084-9.
21. Pan YX, Xu J, Bolan E, etal. Identification of four novel exon 5 splice variants of the mouse mu-opioid receptor gene: Functional consequences of C-terminal splicing. Mol Pharmacol 2005;68:866-75.
22. Abbadie C, Gultekin SH, Pasternak GW. Immunohistochemical localization of the carboxy terminus of the novel mu opioid receptor splice variant MOR-1C within the human spinal cord. Neuroreport 2000;11:1953-7.
23. Abbadie C, Pasternak GW, Aicher SA. Presynaptic localization of the carboxy-terminus epitopes of the mu opioid receptor splice variants MOR-1C and MOR-1D in the superficial laminae of the rat spinal cord. Neuroscience 2001;106:833-42.
24. Schuller AG, King MA, Zhang J, etal. Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1. Nat Neurosci 1999;2:151-6.
25. Rossi G, Pan YX, Cheng J, Pasternak GW. Blockade of morphine analgesia by an antisense oligodeoxynucleotide against the mu receptor. Life Sci 1994;54:PL375-9.
26. Rossi GC, Standifer KM, Pasternak GW. Differential blockade of morphine and morphine-6 beta-glucuronide analgesia by antisense oligodeoxynucleotides directed against MOR-1 and G-protein alpha subunits in rats. Neurosci Lett 1995;198:99-102.
27. Rossi GC, Pan YX, Brown GP, Pasternak GW. Antisense mapping the MOR-1 opioid receptor: Evidence for alternative splicing and a novel morphine-6 beta-glucuronide receptor. FEBS Lett 1995;369:192-6.